ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Clinical trials for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTHRACYCLINE-INDUCED CARDIAC TOXICITY trials appear
Sign up with your email to follow new studies for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart shield: diabetes drug may protect breast cancer Patients' hearts during chemo
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by a common type of chemotherapy (anthracycline) in women with breast cancer. About 100 participants will take either dapagliflozin or a placebo daily during their chemo. Researchers…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: PHASE2 • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Arm cuff may shield heart during chemo
Disease control Recruiting nowThis study tests if briefly restricting blood flow to the arm (using a blood pressure cuff) before chemotherapy can prevent heart damage in lymphoma patients. About 608 adults receiving a common type of chemotherapy (anthracyclines) will be randomly assigned to receive the real t…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: NA • Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III • Aim: Disease control
Last updated May 20, 2026 11:53 UTC